AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05731986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Orthostatic challenge
Description: Designed to invoke an orthostatic response. It begins with the participants lying supine on a specialized bed. The bed is then converted into a chair by raising the head of the bed by 90° and dropping the base of the bed by 90° from the knee.~This position will be maintained for 15 minutes, while hemodynamic measures are continuously recorded. Some of these sessions will be accompanied by spinal stimulation.
Study NCT05731986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biostim-5 transcutaneous spinal stimulation - Mapping
Description: Transcutaneous stimulation of the spinal cord. Two days of mapping will be performed to determine sites for modulation of blood pressure. During each day, with the participant in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C3/4, C5/6, C7/T1, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increase by 5 mA increments up to 100 mA. The frequency will be two or 30 Hz.
Study NCT05731986 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Biostim-5 transcutaneous spinal stimulation - Mapping
Description: Transcutaneous stimulation of the spinal cord. Two days of mapping will be performed to determine sites for modulation of blood pressure. During each day, with the participant in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C3/4, C5/6, C7/T1, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increase by 5 mA increments up to 100 mA. The frequency will be two or 30 Hz.
Study NCT05731986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biostim-5 transcutaneous spinal stimulation - Optimal testing
Description: Based on the mapping sessions, profiles will be established to guide the selection of an optimal site location for blood pressure modulation (within the range of 110-120 mmHg).
Study NCT05731986 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Biostim-5 transcutaneous spinal stimulation - Sham testing
Description: Based on the mapping sessions, a profile that does not elicit a significant blood pressure response, will be used for the sham stimulation.
Study NCT06345274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement Based Care Training and Monthly Consultation
Description: Participating opioid treatment program leaders and treatment providers will receive two measurement-based care implementation strategies: 1) didactic training including a total of four hours of workshop training led by a measurement-based care expert, and 2) monthly consultation calls led by a measurement-based care expert for 6 months.
Study NCT05122975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S48168 (ARM210)
Description: Ryanodine Receptor modulator
Study NCT05122975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo of same size and consistency as S48168 (ARM210)
Study NCT06010160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game Changers for Cervical Cancer Prevention
Description: The peer advocacy training sessions focus on reduction of internalized stigma, disclosure decision making, education on cervical cancer facts and myths, and building skills for cervical cancer prevention advocacy.
Study NCT05805176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHD Therapy
Description: investigational game-play therapy
Study NCT05540132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: Pre-exercise carbohydrate, fast-acting
Study NCT05540132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: super starch
Description: Pre-exercise carbohydrate, slow-acting
Study NCT05082857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional Parents as Teachers (PAT)
Description: A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others.
Study NCT05082857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hybrid PAT model
Description: A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking.
Study NCT05076006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: Active study drug
Study NCT05076006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study NCT06139510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quantitative sensory testing
Description: Quantitative sensory testing is a standard type of pain testing that measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
Study NCT05261646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Stage 1： Hetrombopag lower dose； Hetrombopag higher dose~Stage 2:~Hetrombopag X mg (dose to be determined based on Stage 1 results)
Study NCT05261646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo（Stage 1；Stage 2）
Study NCT06326814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized anti-Factor Bb monoclonal antibody
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
Study NCT06326814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
Study NCT06008314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePNa
Description: Real-time, automated clinical decision support tool for pneumonia (called ePNa)
Study NCT05187689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR + MHL intervention
Description: The intervention will include: 1) a Virtual Reality (VR) interactive and immersive 30-minute session viewed using a low cost VR headset; and 2) an 8-week program of weekly WelTel SMS check-ins managed by Peer Navigators (PNs), weekly WelTel SMS blasts informed by Psychological First Aid (PFA) with mental health literacy (MHL) messages developed with PN, and weekly WelTel web-based secure platform social group discussions on MHL, stress coping, and stigma moderated by PN alongside a trained Coordinator. Weekly MHL WelTel platform moderated discussion foci will address MHL, stigma and stress coping strategies, including self-compassion and other strategies that emerge from the urban refugee youth interviews and focus groups, through diverse methods, including: 'scenarios' mimicking real life situations; a 'question box'; sharing photos demonstrating stress coping strategies; memes; songs; and ways participants interrupted stigma in their daily lives.
Study NCT05187689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group PM+
Description: Participants will attend small groups (5-6 participants with a PN and a coordinator supporting) outdoors with physically distancing, for Group PM+ sessions following the adapted WHO Group-PM+ manual (adaptations made in Phase 1 explain above) 5 weekly 3-hour sessions delivered by PN who will co-facilitate sessions with the Coordinator. Each session has a mechanism of action:~1. Managing stress: mechanism of action-identify goals, learn deep breathing and techniques for stress management~2. Managing problems: mechanism of action-identify 1 solvable practical problem, brainstorm possible solutions together~3. Get going, keep doing: mechanism of action-learn about depression and inactivity, identify and plan small enjoyable activities~4. Strengthen social support: mechanism of action-discuss a range of social support resources, make plan to increase social support~5. Staying well: mechanism of action- this session reviews all of the mechanisms of action in the prior 4 sessions
Study NCT04126135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
Study NCT04126135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
Study NCT05408429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine
Study NCT05408429 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine
Study NCT04753190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Sleep Satiation and Phase Stabilization
Description: All participants will be assigned a 9-h sleep opportunity for the first week of the 2-week study. This will ensure that adolescents are not sleep restricted before living in the laboratory during the second week of the study. The 9-h sleep schedule will be individually timed from his/her averaged wake time (± 15 mins) before the study begins. Assigned bedtime will be 9 h before wake.
Study NCT04753190 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baseline Sleep Satiation and Phase Stabilization
Description: All participants will be assigned a 9-h sleep opportunity for the first week of the 2-week study. This will ensure that adolescents are not sleep restricted before living in the laboratory during the second week of the study. The 9-h sleep schedule will be individually timed from his/her averaged wake time (± 15 mins) before the study begins. Assigned bedtime will be 9 h before wake.
Study NCT04753190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradually Shifted Sleep
Description: For all participants, their assigned baseline sleep/wake schedule will gradually shift earlier over 3 days in the laboratory to facilitate the phase advance shift of the circadian system.
Study NCT04753190 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Gradually Shifted Sleep
Description: For all participants, their assigned baseline sleep/wake schedule will gradually shift earlier over 3 days in the laboratory to facilitate the phase advance shift of the circadian system.
Study NCT04825678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
Study NCT05737069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginine granules 400 mg
Description: Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
Study NCT05737069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen arginine granules 400 mg
Description: Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
Study NCT05737069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginine granules 400 mg (Spedifen)
Description: Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
Study NCT05737069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen arginine granules 400 mg (Spedifen)
Description: Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
Study NCT06135805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinonide 0,05% oral gel
Description: Application of Fluocinonide oral gel on oral syntomatic lesions
Study NCT06135805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of placebo oral gel on oral lesions
Study NCT05106647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduce screen time
Description: The intervention is information provided via email on how to set up an automated response to emails received during their weekend off, reduce screen time for duration of leisure time, and uninstall work applications from their mobile device.
Study NCT06091111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THD, THN
Description: New hybrid absorbing incontinence product for day (THD) and night (THN) use. These are variants of the same product. The intervention product is a novel design that contains reusable elements allowing for a more sustainable product.
Study NCT05306899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Bolus of IV Ketamine 1 mg.kg-1 (= 0.1 ml.kg-1) followed by Infusion of Ketamine 1 mg.kg-1.hour-1 (= 0.5 mL.kg-1.hour-1) for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
Study NCT05306899 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Bolus of IV Saline 0.9% of 0.1 ml.kg-1 followed by Infusion of Saline 0.9% of 0.5 mL.kg-1.hour-1 for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
Study NCT05708755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)
Description: Whole blood assay that evaluates T cell (CD4 and CD8) responses to cytomegalovirus (CMV) antigens via intracellular cytokine staining (ICS).
Study NCT05708755 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Donor-Derived Cell-Free DNA (dd-cfDNA) Assay
Description: Determines the percentage of circulating cell-free DNA (cfDNA) in transplant recipients derived from donor grafts.
Study NCT05708755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Delivered as standard of care for post-lung transplant immunosuppression and infection prophylaxis. Started on the first day post-transplant at a standard dose of 900 mg daily and continued for 12 months. Dose adjustments may be necessary based on renal function and/or adverse effects (e.g. neutropenia). Dose adjustments are standard based on package insert recommendations.
Study NCT06212856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: The group will receive plyometric exercises in a controlled environment. Following, Plyometrics would be performed.~1. Leg hops~2. Tuck jumps~3. Vertical jumps~4. Explosive push-ups~5. Jumping spider~6. Lateral/ diagonal and broad jumps~7. Clapping push-ups~8. Medicine ball presses~9. Rotational throws~10. Vertical and obstacle jumps~11. Box shuffles~12. Chest passes~13. Box jumps~14. Drop jumps~15. Overarm throws
Study NCT06212856 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional
Description: The group will receive conventional exercises in a controlled environment. Following, conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges~4. Squats~5. 500m running
Study NCT06235190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Felix NeuroAI Wristband
Description: The Felix NeuroAI Wristband (Felix) is a wrist-worn, noninvasive, transcutaneous neurostimulation system. Using a proprietary artificial intelligence (AI) algorithm, stimulation will be automatically adapted to patient's needs with the goal to provide full day relief of upper limb tremor.
Study NCT06235190 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham device has the same exterior appearance and components as the Felix device and is used the same way (without delivering the treatment).
Study NCT06060925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: B-mode, color Doppler, shear wave elastography
Study NCT06060925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance spectroscopy
Description: Multifrequency bioimpedance spectroscopy
Study NCT06060925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: High density electromyography
Study NCT06060925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examination
Description: Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing
Study NCT06431594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5733584
Description: GSK5733584 will be administered
Study NCT05005429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required.
Study NCT05929274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 milliampere (mA) from the onset of stimulation and applied for 20 minutes.
Study NCT05929274 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: For the sham condition (sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
Study NCT05343182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Technique
Description: This operation is performed using modified anesthesia care/deep sedation (MAC) for anesthesia. The vestibule is removed to the boundary of Harts line. The surgical flap for this procedure is the Hymen plus 1 cm of the vagina.
Study NCT05343182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Technique
Description: This operation is performed using an Laryngeal Mask Airway (LAM), (modified anesthesia care/deep sedation) for anesthesia. The vestibule is removed 0.5 to 1 cm beyond the boundary of the Hart's line. The Hymen plus 1 cm of the vagina is excised.
Study NCT05777187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: The intervention will consist of clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment. This intervention will alert towards delirium risk informed by history of cognitive impairment and promote 12 evidence based best practices during care for perioperative patients.
Study NCT05964218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food-Body-Mind Intervention
Description: The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
Study NCT04524325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trans men
Description: We are studying the effects of testosterone taken by trans men on mechanisms of blood pressure control and comparing those results to cisgender women that have normal (ie lower) testosterone levels.